- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
We're at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease.
With U.S. troops deployed around the world, it is our mission to both protect U.S. military personnel and serve the international community by reducing risk of HIV-1 infection.
MHRP is at the forefront of the battle against HIV to protect U.S. troops from infection and to reduce the global impact of the disease. While its primary focus is developing a globally effective HIV-1 vaccine, the program provides prevention, care and treatment through the President’s Emergency Plan for AIDS Relief (PEPFAR).
MHRP is centered at the Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Materiel Command.
MHRP was authorized by Congress in 1986, and since has become a leader in international efforts to combat HIV. With five sites in Africa and Asia, the program’s growth has been achieved through the combination of strong vaccine science, the careful development of research sites, and partnerships with key research institutions in the U.S. and host countries.
The integration of prevention, care and treatment has helped MHRP build strong and trusting relationships with the communities in which research is conducted, while providing an ethical framework to conduct HIV clinical research.
The program’s network includes international laboratory and clinical research capabilities. MHRP has developed research sites in Tanzania, Kenya, Nigeria, Uganda and Thailand. MHRP’s main laboratories are located in Rockville, Maryland.
While it may still take another decade to have a globally effective HIV Vaccine, recent advancements give powerful reason for optimism.
Survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives, according to findings from an MHRP study published in the Lancet ID today.
In a new paper, published in the journal BBA Biomembranes, MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant.
Findings from a WRAIR/NIAID led Ebola vaccine clinical trail were published in the New England Journal of Medicine today, highlighting that the vaccine candidate is safe and elicits a robust immune response.
MHRP's Global Health Programs (GHP) collaborated on a special supplement to the latest edition of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).